Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study
Frontiers in Oncology · 19.08.2026 · 16
DOI: 10.3389/fonc.2026.1890752 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Oncology, online erschienen am 19.08.2026. Verfasst von Tiankuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Wuxi branch of Ruijin Hospital Shanghai, Wuxi, Jiangsu, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Irreversible electroporation (IRE) is a promising non-thermal ablative modality for advanced pancreatic cancer (APC). However, whether tumor location influences outcomes remain unclear due to distinct anatomical relationships between the pancreatic head/neck and body/tail. This study compared the safety, efficacy, and survival outcomes of IRE between patients with pancreatic head/neck and body/tail tumors.
Methods
We analyzed a real-world cohort of 63 consecutive patients with advanced pancreatic cancer (comprising primary, post-resection recurrent, and oligometastatic diseases) who underwent percutaneous CT-guided IRE between March 2018 and July 2024. Patients were stratified into the head/neck group (n=39) and the body/tail group (n=24). Baseline characteristics, procedural parameters, adverse events, overall survival (OS), event-free survival (EFS), and tumor marker changes (CA19-9/CEA) were compared.
Results
Median age was 66 years (head/neck) versus 61 years (body/tail) ( P = 0.468). The body/tail group had significantly higher body weight (median 56 vs. 47 kg, P = 0.021) and BMI (median 20.19 vs. 17.99 kg/m², P = 0.021). No significant differences were observed in IRE procedural parameters. Elevated serum amylase was the most common adverse event (61.5% vs. 58.3%, P = 1.000), and complication rates were comparable. Median OS from surgery was 8.7 versus 9.37 months ( P = 0.788), while OS from diagnosis was 22.80 versus 21.32 months ( P = 0.948). Median EFS was 6.00 versus 6.25 months ( P = 0.357). No significant differences were found in 1-month post-IRE CA19–9 or CEA ratio changes ( P = 0.783 and P = 0.295, respectively).
Conclusions
In this cohort of patients with relatively low BMI, percutaneous CT-guided IRE demonstrated comparable safety and efficacy between pancreatic head/neck and body/tail locations. Tumor location alone may not limit IRE feasibility; however, caution is needed when generalizing these findings to Western populations with higher BMI, and larger prospective studies are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology, Wuxi branch of Ruijin Hospital Shanghai, Wuxi, Jiangsu, China.
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Li, T., Liu, X., Shan, Q., Li, J., Huang, W., & Hu, X. (2026). Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1890752
Vancouver
Li T, Liu X, Shan Q, Li J, Huang W, Hu X. Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1890752
BibTeX
@article{Li2026,
author = {Li, Tiankuan and Liu, Xiaoyu and Shan, Qungang and Li, Jingfeng and Huang, Wei and Hu, Xiaoheng},
title = {Does tumor location affect irreversible electroporation outcomes in pancreatic cancer? A head-to-head comparative cohort study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1890752}
}
EUVIMED